Allakos Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-05-15: Form 8-K; Period of report 2025-05-15; Description 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 2.01.
- 2025-04-02: Form 8-K; Period of report 2025-04-01; Description 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; Details 1.01.
- 2025-03-13: Form 8-K; Period of report 2025-03-12; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2025-03-12: Form 8-K; Period of report 2025-03-12; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2025-05-15 | 8-K | 2025-05-15 | 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 2.01 As previously disclosed by Allakos Inc. (the “Company” or “Allakos”) in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 2, 2025, the Company entered into an Agreement and Plan of Merger, dated as of April 1, 2025 (the “Merger Agreement”) with Concentra Biosciences, LLC, a Delaware limited liability company (“Concentra”), and Concentra Merger Sub III, Inc., a Delaware corporation and a wholly owned subsidiary of Concentra (“Merger Sub”). 3.01 The information set forth under Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 3.01. 3.03 The information set forth under Items 2.01, 3.01, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03. 5.01 The information set forth under Items 2.01, 5.02 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01. 5.02 Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Robert Alexander, Ph.D., Robert E. Andreatta, Neil Graham, M.D., Steven P. James, Amy L. Ladd, M.D., Dolca Thomas, M.D. and Paul Walker resigned from the board of directors of the Company and Dr. Alexander, Baird Radford and Adam Tomasi have resigned from their respective positions as officers of the Company. 5.03 Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s certificate of incorporation and bylaws were amended and restated in their entirety, as set forth on Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. | ny20049047x1_8k.htm |
| 2025-04-02 | 8-K | 2025-04-01 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 On April 2, 2025, the Company issued a press release announcing the signing of the Merger Agreement, a copy of which is attached hereto as Exhibit 99.1 and incorporated by reference herein. | d923788d8k.htm |
| 2025-03-13 | 8-K | 2025-03-12 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On March 12, 2025, Allakos Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between January 27, 2025, through March 11, 2025, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). | allk-20250312.htm |
| 2025-03-12 | 8-K | 2025-03-12 | 2.02 Results of Operations and Financial Condition | 2.02 On March 12, 2025, Allakos Inc. (the “Company”) issued a press release reporting its financial results for the fourth quarter ended December 31, 2024. | allk-20250312.htm |
| 2025-01-27 | 8-K | 2025-01-27 | 7.01 Regulation FD Disclosure | 7.01 On January 27, 2025, Allakos Inc. (the “Company”) released an updated corporate presentation. | allk-20250127.htm |
| 2025-01-27 | 8-K | 2025-01-27 | 2.02 Results of Operations and Financial Condition; 2.05 Costs Associated with Exit or Disposal Activities; 7.01 Regulation FD Disclosure | 2.02 On January 27, 2025, Allakos Inc. (the “Company”) issued a press release announcing its estimated, unaudited cash, cash equivalents, and investments balance as of December 31, 2024. 2.05 On January 27, 2025, the Company announced plans to discontinue development of AK006. 7.01 On January 27, 2025, the Company issued a press release announcing that its Phase 1 clinical trial of AK006 in patients with chronic spontaneous urticaria (CSU) did not demonstrate therapeutic activity in patients with CSU. | allk-20250127.htm |